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Background: Sub Saharan African is experiencing the largest increase in the prevalence of type 2 diabetes mellitus
and cardiovascular disease globally. Metabolic syndrome (MetS) is a cluster of risk factors for these conditions. There
is a consistently higher prevalence of cardiometabolic disease among individuals with severe mental illness (SMI)
compared to the general population worldwide .However, it is known from research in high income countries that
screening for MetS in patients with SMI is low. The objective of this study was to document the extent of the
expected low frequency of testing for all the components of the metabolic syndrome (MetS) in patients with SMI in
a low middle income country.
Methods: This was a cross sectional study, undertaken from January to June 2012 on out-patients with SMI who
were treated with antipsychotic medication for at least 6 months. The study measured the proportion of participants
who were tested for MetS in the previous year.
Results: The study included 331 (M: F; 167:164) participants with a mean age of 35.2 ± 11.98 years. The majority
(78.8%) were black South Africans. Only 2 subjects (0.6%) were screened for all five components of MetS. Regarding
the individual components, 99%, 0.6%, 3.9% and 1.8% were screened for raised blood pressure, abdominal obesity,
hyperglycaemia, hypertriglyceridaemia and decreased high density lipoprotein cholesterol respectively.
Conclusion: It is unacceptable that less than one percent of our participants were adequately screened for modifiable
risk factors for type 2 diabetes mellitus and cardiovascular disease which are the most common causes of mortality
among patients with SMI. These results highlight the need for translating guidelines into action in low and middle
income countries.
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Worldwide, individuals with severe mental illnesses
(SMI) such as Schizophrenia and related disorders, have
a consistently higher prevalence of metabolic syndrome
(MetS) than the general population [1,2]. Severe mental
illness (SMI) refers to mental illnesses which are per-
sistent and cause substantial social and/or occupational
dysfunction [3]. MetS is a cluster of risk factors for
cardiovascular disease (CVD) and type 2diabetes. Ac-
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unless otherwise stated.three of the following five components are necessary for
the diagnosis of MetS: increased waist circumference,
raised blood pressure, increased triglycerides, decreased
high density lipoprotein (HDL) cholesterol and raised
plasma glucose [4].
The increased prevalence of MetS in individuals with
SMI has been attributed to several factors including the
mental illness itself, the adverse effects of antipsychotic
medication and traditional risk factors for CVD and type
2 diabetes mellitus such as obesity, unhealthy high fat
low fibre diets, physical inactivity and smoking, which
are common in patients with SMI [5].
Antipsychotics are an important cardiometabolic risk
factor for MetS with a variable risk for MetS amongl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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side effects of second generation antipsychotics (SGAs)
showed that olanzapine and clozapine were associated
with the highest risk for elevations in weight, cholesterol
and glucose [7]. The metabolic risk associated with
SGAs led to United States Food and Drug Administration
(FDA) black box warnings and the development of several
international treatment guidelines for routine metabolic
screening and monitoring in patients taking SGAs [8]. Al-
though the evidence for the metabolic side effects of first
generation antipsychotics (FGAs) is not as robust as that
for SGAs, there is also evidence in the early literature to
confirm the metabolic risk profile of FGAs [9].
The extent and frequency of screening is debatable,
but there is global consensus that baseline metabolic
screening should form part of the standard of care
for all patients with a regular prescription of an anti-
psychotic [1,2,5-8].
However, reports of metabolic screening practices in
large cohorts of patients from high income countries
(HIC) have shown that metabolic testing remains inad-
equate despite widespread dissemination of the guide-
lines and a high level of awareness of the metabolic risks
associated with SGA medications among psychiatrists
[10-12]. A meta-analysis of screening practices from five
HIC countries (United States of America (USA), United
Kingdom (UK), Australia, Canada and Spain) found that
routine baseline screening was above 50% for blood
pressure and triglycerides only and that glucose and
cholesterol were measured in less than 50% of individ-
uals with mental illness. No data from low middle income
countries (LMIC) was included in this meta-analysis [10].
The 2005 South African guidelines for managing
metabolic abnormalities in patients with schizophrenia
recommended monitoring anthropometric measurements,
plasma glucose and serum lipids prior to initiation of SGA
medication, and at 6 weeks, four months and twelve
months thereafter [13].
Despite these recommendations, a study from the
Western Cape in South Africa showed that in outpa-
tients with SMI, no patient had a waist circumference
measurement. In that study, anthropometric measures
were examined without blood tests [14]. Marsay and
Szabo also found that four months after initiation of
Olanzapine there was so little screening that data inter-
pretation had no value [15].
This study was motivated by the dearth of information
on the frequency of monitoring for all the components
of the MetS in patients with a SMI nationally as well as
the general paucity of information from LMIC. It is not
known whether the frequency of metabolic testing for all
the components of MetS in patients with a SMI in South
Africa is similar to those observed in European and North
American countries. Even less is known about medical carefor patients with a SMI who have no public or private
health insurance.
The aim of this study therefore, was to determine the
frequency of testing for all the components of MetS in




This was a cross sectional study, undertaken from January
to June 2012 in outpatients with SMI, aged 18–65 years
who were treated with antipsychotics for at least 6 months
and attending the psychiatric unit at King Edward VIII
Hospital in Durban, KwaZulu - Natal South Africa.
This public health facility is the second largest hospital
in the Southern hemisphere and is the main teaching
hospital of the Nelson R Mandela School of Medicine.
The hospital serves predominantly uninsured patients
from disadvantaged backgrounds. KwaZulu - Natal prov-
ince has the highest prevalence of HIV disease in the
country, resulting in a high burden of psychiatric disor-
ders associated with HIV [16]. The hospital’s psychiatric
outpatient clinic provides care and treatment at both pri-
mary and specialised levels because community - based
mental health services in the district are under-developed
and poorly funded. The clinic serves as a primary mental
health care clinic for individuals residing in close proxim-
ity to the hospital because the local clinic is overcrowded
and there is frequently a shortage of SGAs. Psychiatric
registrars run the clinic under the supervision of specialist
psychiatrists.
In this study the following were defined as SMI:
schizophrenia, bipolar 1 mood disorder, major depressive
disorder with psychotic features, psychotic or mood dis-
order associated with a general medical condition and
schizoaffective disorder. The daily outpatient attendance
registers in the unit were used to identify adult patients
aged 18–65 years with a continuous prescription of an
antipsychotic for at least six months.
Data collection
All consenting participants provided information for a
questionnaire including information regarding age, gen-
der, ethnicity, employment status, cigarette smoking,
current or past diagnosis of hypertension, diabetes and
HIV disease. Available information on waist circumfer-
ence, blood pressure, weight, cholesterol and glucose
testing in the preceding year was recorded. Documenta-
tion in the psychiatric case notes of testing for any of
the Mets components (blood pressure, waist circumfer-
ence fasting blood glucose and lipids) was considered to
be evidence that testing took place. We did not search
the hospital laboratories’ database for glucose and lipid
testing. Participants’ records were also examined to obtain
Table 1 Demographic and clinical characteristics of study










Age (years) mean ± SD 35.2 ± 11.98
Age distribution n (%)
18-30 years 141 (42.6%)
31-40 years 82 (24.8%)
41-50 years 60 (18.1%)





Disability grant/old age pension 63 (19%)
Diagnosis n (%)
Schizophrenia 163 (49.3%)
Major Depressive Disorder 15 (4.5%)
Bipolar Mood Disorder 49 (14.8%)
Schizoaffective Disorder 36 (10.9%)
Mood/psychotic disorder due to a general
medical condition
68 (20.5%)










History of [n (%)]:
Smoking 77 (23.3%)
HIV disease 67 (20.2%)
Hypertension 12 (3.6%)
Type 2 diabetes 5 (1.5%)
Results expressed as n (%) or mean ± SD.
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scribed. Compulsory hospital audits have ensured that the
psychiatric case records are legible and contained the infor-
mation required for this study. Psychiatric records are filed
in the psychiatric clinic and not in the general hospital fil-
ing system. The records are thus readily available.
Measures
The study measured the proportion (%) of participants
who were tested for the components of MetS in the pre-
vious year.
Statistical analysis
Statistical analysis was undertaken using the Statistical
Package for Social Sciences (SPSS version 19). Means
and standard deviations were computed for continuous
variables and percentages or proportions for categorical
variables. Descriptive statistics (percentages or proportions)
were used to report the results. Participants who had fast-
ing glucose or lipid test results and who were taking olan-
zapine or clozapine were compared to participants taking
other antipsychotics using chi-squared tests.
This study was approved by the Biomedical Research
Ethics Committee of the University of KwaZulu - Natal.
Results
This analysis included 331 participants with SMI who were
treated with an antipsychotic for at least six months.
Demographic and clinical characteristics of the participants
are shown in Table 1. The gender distribution was equal.
Most participants were of black African ancestry (78.8%).
The mean age of the study subjects was 35.2 ± 11.98 years
and 40% of the participants were in the 18–30 year age
group. Smoking, a modifiable risk factor for cardiovascular
disease was identified in 23.3% (n = 77) of the participants
and 20.2% were HIV positive.
Three out of every four participants were either un-
employed or on state disability grants. Just over two
thirds of the group were treated with a SGA. The most
and least commonly prescribed antipsychotics were ris-
peridone (38%) and aripiprazole (3%), respectively. Cloza-
pine was prescribed for 15 (4.5%) and olanzapine for 13
(3.9%) of the 331 participants.
Of the 331 participants only 2 (0.6%) were screened
for all five components of MetS (Table 2). The most
frequently monitored component of MetS was blood
pressure (99%) and the least frequent was waist circum-
ference (0.6%).The majority had a random plasma glu-
cose test record in the last year (96.6%) but fasting
glucose testing was infrequent. Participants who had a case
note record of fasting glucose (olanzapine 53.8%, clozapine
15.4%, risperidone 15.4%, chlorpromazine 7.7%, haloperi-
dol 7.7%, p < 0.001) or lipids (olanzapine 33.3%, clozapine
50%, risperidone 16.7%, p < 0.001) were significantly more
Table 2 Rates of screening forMetS components in the
past year in study participants (n =331)
MetS Component Screened n (%)
Blood Pressure 328 (99%)
Fasting blood glucose (Random blood glucose) 13 (3.9%) 320 (96.6%)
Fasting serum lipids 6 (1.8%)
Waist circumference 2 (0.6%)
All components 2 (0.6%)
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participants taking olanzapine or clozapine only 8% and
7% respectively had psychiatric case note records of both
fasting glucose and lipid tests.
Forty two per cent (n = 138) of patients with SMI re-
lied on the hospital’s psychiatric clinic for their general
medical care; only 10.5% visited their general practi-
tioner for medically related illnesses (Table 3).
Stratification of testing by age and site of general med-
ical care did not show any differences in the monitoring
of older versus younger patients and patients who relied
on the psychiatric clinic for their physical health care
compared to those who did not.
Discussion
This study found very low rates of screening for all the
components of MetS in patients with SMI treated with
antipsychotics from a LMIC; moreover except for blood
pressure, screening for the other components of MetS
was unacceptably low. The finding that only 0.6% of par-
ticipants were screened for all the components of MetS
is to the best of our knowledge, the lowest recorded in
the literature. Direct comparisons with other regions are
not reliable because of the substantial heterogeneity in
the study settings, samples, within country differences,
time frames for screening and selective reporting of indi-
vidual MetS components in the literature. For example,
only eight of the 48 studies in the meta-analysis by Mitchell
et al. [10] reported on fasting samples. Nevertheless, data
from HIC are presented to contextualise our findings.
High rates of metabolic screening have been reported
in Veterans Affairs (VA) settings in the USA [17-19] andTable 3 Treatment settings for general medical care for
study participants (n = 331)
Site n (%)
General Practitioner 35 (10.6%)
Psychiatric clinic 138 (41.7%)
Other clinic e.g. medical/surgical follow up
clinic in the hospital
121 (36.5%)
Local Primary/Community health clinic 37 (11.2%)post quality improvement programmes implementation
in Spain [20] and the UK [21]. In a VA setting, Khatana
et al. [17] found that about 80% of patients with a SMI
were monitored for all components of the MetS and
similarly Shi and colleagues [18] report that 75.8% of
patients with schizophrenia received glucose and lipid
monitoring using the Veterans Integrated Service Network
(VISN) 16 electronic records of the Veterans Health Ad-
ministration. In contrast, rates of below 30% for glucose
and 15% for lipids have been reported among US Medic-
aid [22] and commercial insurance enrollees [23]. A likely
explanation for this discrepancy is the presence of a pri-
mary care clinic which is co-located and integrated into
the outpatient mental health clinic at VA medical centres,
the older age of the participants in the VA system and
their more effective metabolic monitoring programmes.
Bobes’ group [20] showed that waist circumference, lipid
and glucose profiles were recorded in 33.2%,72.5% and
73.2% respectively of clinical charts following the dissem-
ination of the Spanish consensus on physical health in pa-
tients with schizophrenia. In the UK, Gonzales et al. [21]
report that glucose and lipids were monitored in 72.6%
and 52.8% of patients respectively following a monitoring
prompt and educational intervention programme. How-
ever, Mackin et al. [24] found that 0% of patients had a
record of waist circumference and less than 10% had a
blood glucose or lipid result recorded in a study from the
Northeast of England. Similarly an Australian audit of dis-
charged patients with schizophrenia found that only 3%
had a post prandial blood sugar and 7.5% triglycerides and
cholesterol recorded in their case notes. Waist circumfer-
ence was not recorded in this study [25].
Therefore, our findings indicate local screening rates
that are substantially lower than the general finding of
suboptimal metabolic monitoring for patients taking
antipsychotics from HIC [10]. We reported on fasting
laboratory samples, included an overall rate of screening
for all components of MetS and excluded weight or BMI
as a measure of central adiposity which could have con-
tributed to our low frequency of screening.
It is disappointing that only 3.9% of the participants
had fasting blood glucose and 1.8% had fasting lipid
(triglycerides, HDL cholesterol) tests given that both
glucose and lipid abnormalities can occur without weight
gain [26]. Furthermore, in spite of previous reports that
clozapine and olanzapine are associated with substan-
tially greater metabolic side effects than other SGAs less
than 10% of the patients treated with clozapine or olan-
zapine in this study had both glucose and lipid tests [7].
In keeping with the study by Gul [27] there was a dis-
crepancy between the frequencies of fasting and non -
fasting blood tests in patients with mental illness. A likely
explanation is that it is not routine for patients to be
asked to attend follow up appointments in a fasting state
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pital for repeat fasting blood tests.
More than three quarters (79%) of our participants
were either unemployed or on a state disability grant.
Previous studies have demonstrated that there is an in-
verse relationship between socioeconomic class and the
prevalence of MetS [28]. Poor access to information and
little understanding of the impact of lifestyle modifica-
tion on cardiovascular risk has been shown to be associ-
ated with poverty and illiteracy among the general
population of India [29]. The low frequency of metabolic
monitoring in the current study may be partially attrib-
utable to the inadequate health education received by
the patients who were mostly unemployed and with no
health insurance.
Our findings also highlight some barriers to screening
such as the lack of integrated mental and medical ser-
vices locally and the poorly developed community –
based psychiatric services resulting in an over reliance
on institutional care. Many patients relied on the hospi-
tal’s psychiatric clinic for their general medical care.
Poorer access to medical care for patients with a mental
illness compared to patients without a mental illness has
been documented in other settings [30]. The availability
of medical services within the psychiatric clinic as well
as dedicated metabolic monitoring clinics is associated
with higher monitoring rates [17,31]. The South African
public health care system is currently struggling to cope
with very high case loads and patients experience long
waiting times before being attended to. A fee, which is
dependent on the income of an individual, is levied for
attending the hospital but patients who cannot pay are
not turned away. There is a laboratory located within
the hospital which is part of the national health labora-
tory service. The institution is liable for the cost of ser-
vices rendered by the laboratory. Individual patients do
not pay for laboratory testing but doctors at our hospital
are encouraged to order tests based on clinical indica-
tion and where the results of testing impact on further
management. The attending doctor is responsible for all
physical examinations in the psychiatric clinic. Although
phlebotomists are employed throughout the hospital, a
phlebotomist is not allocated to the psychiatric clinic
and doctors are responsible for the drawing of bloods
from the patients they attend to. A possible solution to
improve our monitoring rates may be to introduce a
model of shared care. A nurse – run metabolic monitor-
ing programme has proved to be successful in the
United States [32]. Mental health providers in LMIC
need to extend their roles beyond taking care of the
mental health of their patients and assume some respon-
sibility for the physical health of their patients. Identifi-
cation of patients at risk for MetS through screening
should take place at the point of care for the mental illness.Patients with a SMI have a 2–3 fold higher prevalence
of type 2diabetes and CVD [1]. Smoking, a modifiable risk
factor for CVD was identified in one in five of the partici-
pants in this study. A recent study showed that all CVD
risk factors except for cholesterol were higher in patients
with SMI than in the general population of the United
States [33]. Furthermore, Lozano et al. [34] report that, al-
though global disability and deaths due to diabetes and
CVD are projected to increase by 2020, the largest in-
creases in deaths are predicted for Sub-Saharan Africa
(SSA). SSA is experiencing one of the most rapid rates of
urbanization worldwide which may be contributing to a
rising prevalence of non- communicable diseases (NCDs)
in this region [35]. Against this background of a surge in
the prevalence of NCDs in the general population, the
mentally ill in SSA form part of a particularly high risk
group for future CVD and diabetes mellitus. Our main
concern therefore, is that because of the inadequate
screening received by the overwhelming majority of pa-
tients in this study the associated risks will, in all likeli-
hood go undetected.
This study has several limitations. The study was con-
ducted in one general hospital and the generalizability of
our results may be questionable. Our results are dependent
on the accuracy of the information contained in the psychi-
atric case notes. It is likely that individuals may have been
screened by health care providers in this or other hospitals
in the district, but, that these results were not communi-
cated to the attending psychiatrist.
Conclusions
Our findings are clinically significant although they were
not entirely unexpected. The significance of our study is
that it quantifies the extent of the under-recognition of
modifiable risk factors for CVD such as central obesity,
hypertension, dyslipidemia, and hyperglycemia among
patients with SMI. This study emphasises the lack of
translation of guidelines to action for the prevention,
early detection and treatment of these risk factors in a
particularly high risk group of individuals. It highlights
the importance of documenting the frequency of screen-
ing because this will hopefully support the allocation of
resources for improved screening in LMIC.
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